A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Dec 2017
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 14 Nov 2017 Planned End Date changed from 17 Jun 2019 to 13 Nov 2019.
- 22 Sep 2017 Planned initiation date changed from 24 Jun 2017 to 29 Dec 2017.
- 10 Apr 2017 New trial record